Ticker

Profitability This table compares SQZ Biotechnologies and Cortexyme's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets SQZ Biotechnologies -369.96% -119.83% -59.90% Cortexyme N/A -70.96% -63.53% Valuation and Earnings This table compares SQZ Biotechnologies and Cortexyme"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio

Profitability This table compares NKGen Biotech and SQZ Biotechnologies' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% SQZ Biotechnologies -369.96% -119.83% -59.90% Valuation and Earnings This table compares NKGen Biotech and SQZ Biotechnologies"s revenue, earnings per share and valuation. Gross Revenue

Profitability This table compares SQZ Biotechnologies and NKGen Biotech's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets SQZ Biotechnologies -369.96% -119.83% -59.90% NKGen Biotech N/A N/A -479.36% Valuation and Earnings This table compares SQZ Biotechnologies and NKGen Biotech"s top-line revenue, earnings per share (EPS) and valuation.

Institutional and Insider Ownership 0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds,

Volatility and Risk SQZ Biotechnologies has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Profitability This table compares SQZ Biotechnologies and LadRx's net margins, return on